Cargando…

Factors associated with non-compliance with breastfeeding recommendation: a retrospective survey in hepatitis B virus-infected mothers who had taken Nucleos(t)ide analogs during pregnancy

BACKGROUND: We encourage Hepatitis B virus-infected mothers to breastfeed postpartum, even when continuing pregnancy category B nucleos(t)ide analogs (NAs) treatment. However, a large proportion of the Hepatitis B virus-infected mothers were noncompliant with this breastfeeding recommendation. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Er-Mei, Xiao, Li-Xin, Xu, Zhen, Mo, Zhi-Shuo, Li, Jia-Qian, Mei, Yong-Yu, Lin, Chao-Shuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359301/ https://www.ncbi.nlm.nih.gov/pubmed/34384374 http://dx.doi.org/10.1186/s12884-021-04020-z

Ejemplares similares

The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs
por: Gupta, Nidhi, et al.
Publicado: (2014)

The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients
por: Xu, Wen-Xiong, et al.
Publicado: (2021)

Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
por: Liu, Li
Publicado: (2020)

Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2018)

Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
por: Siakavellas, Spyros, et al.
Publicado: (2021)

Compliance of mothers' breastfeeding and complementary feeding practices with WHO recommendations in Turkey
por: Demir, Gülperi, et al.
Publicado: (2020)

Predictors of Sustained Virologic Response after Discontinuation of Nucleos(t)ide Analog Treatment for Chronic Hepatitis B
por: Peng, Jie, et al.
Publicado: (2015)

Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss
por: Xue, Yan, et al.
Publicado: (2021)

Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs
por: Li, Tao, et al.
Publicado: (2018)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
por: Lin, Ching-Chung, et al.
Publicado: (2019)

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
por: Wei, Yanyan, et al.
Publicado: (2019)

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2021)

Antiviral activities of two nucleos(t)ide analogs against vaccinia and mpox viruses in primary human fibroblasts
por: Dsouza, Lara, et al.
Publicado: (2023)

Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population
por: López-Cortés, Luis F., et al.
Publicado: (2014)

Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy
por: Osiowy, Carla, et al.
Publicado: (2016)

Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2021)

Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2022)

Antiviral activities of two nucleos(t)ide analogs against vaccinia, mpox, and cowpox viruses in primary human fibroblasts
por: Dsouza, Lara, et al.
Publicado: (2023)

The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis
por: Wen, Xiaotong, et al.
Publicado: (2021)

Influence of the COVID-19 pandemic on breastfeeding support for healthy mothers and the association between compliance with WHO recommendations for breastfeeding support and exclusive breastfeeding in Japan
por: Nanishi, Keiko, et al.
Publicado: (2022)

Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation
por: Xie, Yandi, et al.
Publicado: (2023)

Dynamics of Serum Pregenome RNA in Chronic Hepatitis B Patients Receiving 96-Month Nucleos(t)ide Analog Therapy
por: Tao, Yachao, et al.
Publicado: (2022)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients
por: Zhang, Chi, et al.
Publicado: (2016)

Frequency and Mutation Patterns of Resistance in Patients with Chronic Hepatitis B Infection Treated with Nucleos(t)ide Analogs in Add-On and Switch Strategies
por: Sayan, Murat, et al.
Publicado: (2011)

The efficiency of low-dose hepatitis B immunoglobulin plus nucleos(t)ide analogs in preventing posttransplant hepatitis B virus recurrence
por: VATANSEVER, Sezgin, et al.
Publicado: (2019)

The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
por: Wang, Mian, et al.
Publicado: (2021)

The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment
por: Wu, Lina, et al.
Publicado: (2021)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity
por: Pastuch-Gawołek, Gabriela, et al.
Publicado: (2019)

Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues
por: Wang, Yang, et al.
Publicado: (2022)

Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients
por: He, Li-Ting, et al.
Publicado: (2016)

Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis B
por: Wang, Fa-Da, et al.
Publicado: (2022)

Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study
por: Li, Yueyue, et al.
Publicado: (2021)

HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study
por: Hu, Peng, et al.
Publicado: (2018)

Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis
por: Chan, Henry L. Y., et al.
Publicado: (2016)

Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score
por: Magalhães-Costa, Pedro, et al.
Publicado: (2016)

Circulating miR-122 Is a Predictor for Virological Response in CHB Patients With High Viral Load Treated With Nucleos(t)ide Analogs
por: Wu, Yin, et al.
Publicado: (2019)

Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy
por: Murata, Ayato, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oe46d7mkek2kc5t7n7vk4csjbb